StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
Huagongshe Open Project:[email protected]KI-Anbindung: llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.7.8
  1. Startseite
  2. /Verbindung

Cethromycin

HCID 156417
NotizenReaktionen
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
205110-48-1
Standard-SMILES
CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OCC=Cc2cnc3ccccc3c2)C[C@@H](C)C(=O)[C@H](C)[C@H]2NC(=O)O[C@@]21C
InChIKey
PENDGIOBPJLVBT-AMXFZXBBSA-N
Summenformel
C42H59N3O10
Durchschnittliche Molmasse
765,9 g/mol
Monoisotopische Masse
765,42004509

Überblick

Cethromycin is a 3-keto (ketolide) derivative of erythromycin A with an 11,12-carbamate group and an O-6-linked aromatic ring system. Cethromycin represents a joint development effort by Abbott Laboratories, Taisho Pharmaceuticals, and Advanced Life Sciences, intended to be marketed under the trade name Restanza for the treatment of community-acquired pneumonia. However, after completing phase III clinical trials, it was deemed safe but not sufficiently efficacious by the FDA. Since this time, cethromycin has received FDA orphan drug designations for the prophylactic treatment of anthrax inhalation, plague due to Yersinia pestis, and tularemia due to Francisella tularensis. It has also been investigated, by itself or together with [zoliflodacin], for the treatment of gonorrhea, and was recently suggested as a possible treatment for liver-stage Plasmodium sporozoite infection.

Namen und Bezeichner

Bevorzugter Name
Cethromycin
IUPAC
(1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-1,5,7,9,11,13-hexamethyl-9-(3-quinolin-3-ylprop-2-enoxy)-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
Englischer Name
CETHROMYCIN
Summenformel
C42H59N3O10
Molmasse
765.93

Namen und Synonyme

Cethromycin205110-48-1cethromycinecetromicinaABT 773Abbott-195773ABT-773DTXSID00870225J0086219X6A-195773cethromycinum(1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-1,5,7,9,11,13-hexamethyl-9-(3-quinolin-3-ylprop-2-enoxy)-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
Weitere Namen anzeigen
RestanzaquinerythromycinCETHROMYCIN(ABT-773)11-Amino-11-deoxy-3-oxo-5-o-desosaminyl-6-o-[1'-(3'-quinolyl-2'-propenyl)] erythronolide A 11,12-cyclic carbamate2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyloctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-
A 195,773A-195,773CHEBI:29506(1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl)oxy-2-ethyl-1,5,7,9,11,13-hexamethyl-9-(3-quinolin-3-ylprop-2-enoxy)-3,17-dioxa-15-azabicyclo(12.3.0)heptadecane-4,6,12,16-tetroneRefChem:575348DTXCID801511050(1S,2R,5R,7R,8R,9S,11R,13R,14R)-8-((2S,3R,4S,6R)-4-Dimethylamino-3-hydroxy-6-methyloxan-2-yl)oxy-2-ethyl-1,5,7,9,11,13-hexamethyl-9-((E)-3-quinolin-3-ylprop-2-enoxy)-3,17-dioxa-15-azabicyclo(12.3.0)heptadecane-4,6,12,16-tetrone(1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl)oxy-2-ethyl-1,5,7,9,11,13-hexamethyl-9-((E)-3-quinolin-3-ylprop-2-enoxy)-3,17-dioxa-15-azabicyclo(12.3.0)heptadecane-4,6,12,16-tetrone

Eigenschaften

Berechnete Struktureigenschaften

XLogP
5,4
Polarare Oberfläche (TPSA)
163 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
12
Frei drehbare Bindungen
8
Schwere Atome
55
Formalladung
0
Komplexität
1.410

Physikochemische Eigenschaften

Schmelzpunkt
211 · 211-213°
Siedepunkt
927.1 · 927.1±65.0 °C(Predicted)
Dichte
1.22 · 1.22±0.1 g/cm3(Predicted)
storage temp.
-20 °C · Store at -20°C
Aggregatzustand
Solid
pka
10.84 · 10.84±0.70(Predicted)
Farbe
White to off-white

Chemie und Industrie

Pharmakologische Informationen

Protein BindingCethromycin displays 86.7 to 95.6% human plasma protein binding over a range of concentrations between 0.1 to 30.0 μg/ml.
Pharmacodynamics · 1 Eintrag

Cethromycin binds to the 50S subunit of the bacterial ribosome to inhibit both ribosome assembly and bacterial protein synthesis. Adverse effects such as diarrhea, nausea, vomiting, and headache may be due to off-target inhibition of molecules within mammalian cells.

Mechanism of Action · 1 Eintrag

Respiratory tract infections can be caused by numerous strains of bacteria, requiring careful consideration of treatment and antibiotics effective against a broad spectrum of potential pathogens. Cethromycin, like other macrolide antibiotics, binds to the 23S rRNA of the 50S subunit of the bacterial ribosome. This binding, primarily mediated through regions II and V of the rRNA, occludes the peptide exit tunnel and inhibits bacterial protein synthesis. In addition, cethromycin is capable of binding to ribosomal intermediates during ribosome biogenesis, inhibiting the formation of functional 70S bacterial ribosomes. Due to the sequence and structural similarity of ribosomes between species, cethromycin displays broad-spectrum activity against diverse Gram-positive, Gram-negative, and atypical bacteria.

Biological Half-LifeCethromycin given in five oral doses of 150 or 300 mg has a plasma half-life of 4.85 ± 1.10 and 4.94 ± 0.66 hrs, respectively. A single oral dose of 150 mg produced a measured half-life of 5.66 ± 0.77 hrs.
Metabolism/Metabolites · 1 Eintrag

Extensive studies of cethromycin metabolism have not been conducted, although one study identified seven metabolites within feces of patients administered a single 150 mg oral dose. The major recovered products were unchanged cethromycin and an inactive N-desmethyl metabolite. It is likely that most of the metabolism occurs in the liver and is mediated, at least in part, by CYP3A4.

MeSH Pharmacological ClassificationSubstances that inhibit the growth or reproduction of BACTERIA.

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen

Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.

Notizen zur Verbindung

Wird geladen…

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
205110-48-1
PubChem CID
156417
DTXSID
DTXSID00870225
ChEMBL
CHEMBL3989904
Absorption, Distribution and Excretion · 4 Einträge

Cethromycin displays non-linear absorption kinetics. In healthy adults administered 150 mg cethromycin orally once daily for five doses, the calculated Cmax, Tmax, and AUC0-24 values were 0.181 ± 0.084 μg/ml, 2.01 ± 1.30 hrs, and 0.902 ± 0.469 μg\*h/ml, respectively. Similarly, the corresponding values for a 300 mg dose were 0.500 ± 0.168 μg/ml, 2.09 ± 0.03 hrs, and 3.067 ± 1.205 μg\*h/ml, respectively. In another study using a single oral dose of 150 mg cethromycin, the Cmax was 318 ± 161 ng/ml, the Tmax was 1.79 ± 0.50, the AUC0-24 was 1596 ± 876 ng\*h/ml, and the AUC0-∞ was 1662 ± 907 ng\*h/ml.

Cethromycin is primarily excreted by the biliary route, with 87.2% of an initial dose recovered in feces and only 7.0% in urine. Unchanged cethromycin accounted for 35.7% of the radioactivity recovered in feces and an N-desmethyl metabolite for 39.8%; the remaining radioactivity was approximately evenly divided between three minor metabolites and a group of uncharacterized additional products.

Cethromycin given in five 150 mg oral doses had an apparent volume of distribution at the terminal elimination phase of 1433 ± 843 L, and an apparent steady-state volume of distribution of 1453 ± 997 L. The corresponding values for a 300 mg dose was 761 ± 293 L and 769 ± 272 L. Cethromycin is known to accumulate in the epithelial lining fluid and alveolar cells, as well as within polymorphonuclear leukocytes.

Cethromycin clearance in patients receiving a once-daily oral dose of 300 mg is reported to be approximately 63 L/h.

Anwendungen · 2 Einträge

BeschreibungCethromycin (formerly ABT-773) is a ketolide antibiotic originally developed by Abbott in the late 1990s, but abandoned in 2002. Since 2004, Advanced Life Sciences has promoted current development of cethromycin. The ketolides are structurally derived from erythromycin A and are designed to overcome resistance to macrolides. One of the main features is the lack of the neutral sugar L-cladinose at position 3 of the erythonolide ring, which is replaced by a keto group (thus giving rise to the class name). Lack of the L-cladinose moiety results in better drug absorption and less gastric irritation through improved acid stability.

VerwendenAntibacterial.

Anbieter14 Anbieter

Shaanxi Cuikang Pharmaceutical Technology Co., Ltd+86-13119157289 · [email protected]
南京世洲生物科技有限公司025-025-85560043 17301488900 · [email protected]
上海赛可锐生物科技有限公司021-58000709 13120558703 · [email protected]
玺标(上海)科技有限公司18512111473 18512111473 · [email protected]
上海喀露蓝科技有限公司18149758185 18149758185 · [email protected]
上海陶术生物科技股份有限公司+1-781-999-5354; +1-00000000000 · [email protected]
上海波以尔化工有限公司021-50182298 021-50180596 · [email protected]
浙江珲达生物科技有限公司0571-89903022 18679456698 · [email protected]
Shanghai Acmec Biochemical Technology Co., Ltd.+86-18621343501 · [email protected]
范德(北京)生物科技有限责任公司15911056312 · [email protected]
SHANGHAI KEAN TECHNOLOGY CO., LTD.+8613817748580 · [email protected]
BOC Sciences+1-631-485-4226 · [email protected]
南京世洲生物科技有限公司18351873721 · [email protected]
InvivoChem+1-708-310-1919 +1-13798911105 · [email protected]